Cannabis
VIVO Cannabis Receives Conditional Approval to Graduate to the Toronto Stock Exchange
VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO” or the “Company“) is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the “TSX“) to graduate from the TSX Venture Exchange (the “TSXV“) and list its common shares on the TSX.
“The TSX is a premier destination for publicy traded companies and this listing represents a significant milestone for VIVO,” said Barry Fishman, CEO. “It also demonstrates our long-term commitment to increasing investor awarness and generating shareholder value as we continue to drive sales in our premium family of brands including Canna Farms™, Beacon Medical™, Fireside™ and Lumina.”
Final approval of the listing is subject to the Company meeting certain conditions required by the TSX on or before February 6, 2020. Upon receipt of final TSX approval, VIVO’s common shares will be delisted from the TSXV and begin trading on the TSX under the symbol “VIVO.”
SOURCE VIVO Cannabis Inc.
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE2 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis1 day ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt20 hours ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace